For the Media
Dr. Hans-Peter Kiem is a member of Fred Hutch's Clinical Research Division. His research is focused on stem cell and transplantation biology, cell and gene therapy and the development and use of novel gene editing technologies. Dr. Kiem's overall goal has been the development of improved treatment approaches for patients with genetic and infectious diseases and cancer.
Overview of Hans-Peter Kiem's Research Focus
His research has focused on stem cell and transplantation biology, cell and gene therapy and the development and use of novel gene editing technologies.
Hans-Peter Kiem - Brief Curriculum Vitae
Appointments, affiliations and researcher interests
Research combines basic and translational research directed at understanding and eliminating major barriers to successful allogeneic hematopoietic stem cell transplantation.
Clinical Research Division
Researchers conduct laboratory and patient-oriented research to better understand the mechanisms that drive cancer and other human diseases. Integrating a variety of disciplines, our investigators are continually developing new therapeutic approaches and leading clinical trials that help move discoveries from laboratory to patient. Our pioneering research has saved hundreds of thousands of lives.
At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch’s pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation’s first National Cancer Institute-funded cancer prevention research program, as well as the clinical coordinating center of the Women’s Health Initiative and the international headquarters of the HIV Vaccine Trials Network.